<h4>Background</h4>Regorafenib alone has shown limited efficacy in some cases of colorectal cancer (CRC), while the use of programmed cell death protein 1 (PD-1)/programmed cell death-ligand 1 (PD-L1) inhibitors is becoming increasingly common in cancer treatment. This evidence concerns the gene PDCD1 and colorectal cancer.